The effects of dopaminergic D2 stimulation and blockade on smoking behavior

Experimental and Clinical Psychopharmacology

Volumn 7, Issue 1, 1999, Pages 72-78

  Caskey, Nicholas H ^a,b   Jarvik, Murray E ^a   Wirshing, William C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; DOPAMINE RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHARMACOLOGICAL BLOCKING; RANDOMIZED CONTROLLED TRIAL; SMOKING; DRUG ANTAGONISM; DRUG POTENTIATION; MIDDLE AGED; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE;

ADULT; BROMOCRIPTINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; RECEPTORS, DOPAMINE D2; SMOKING;

EID: 0032589021     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.7.1.72     Document Type: Article

References (24)

1. Barnes, T. R. E., & Braude, W. M. (1985). Towards a more reliable diagnosis of akathisia (reply). Archives of General Psychiatry, 43, 1016.
2. Carr, L. A., & Basham, J. K. (1991). Effects of tobacco smoke constituents on MPTP-induced toxicity and monoamine oxidase activity in the mouse brain. Life Sciences, 48, 1173-1177.
3. Clarke, P. B. S. (1990). Mesolimbic dopamine activation: The key to nicotine reinforcement. Ciba Foundation Symposium, 152, 153-162.
4. Clarke, P. B. S. (1992). Recent advances in understanding the actions of nicotine in the central nervous system. Journal of the National Cancer Institute Monograph, 2, 229-238.
5. Cohen, J. (1988). Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Erlbaum.
6. Corrigall, W. A. (1991). Understanding brain mechanisms in nicotine reinforcement. British Journal of Addiction, 86, 507-510.
7. Corrigall, W. A., & Coen, K. M. (1991). Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology, 104, 171-176.
8. Dawe, S., Gerada, C., Russell, M. A. H., & Gray, J. A. (1995). Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology, 117, 110-115.
9. Fahn, S., Elton, R. L., & Members of the UPDRS Development Committee. (1987). Unified Parkinson's Disease Rating Scale. In S. Fahn, C. D. Marsden, M. Goldstein, & C. D. Calne (Eds.), Recent developments in Parkinson's disease (Vol. 2, pp. 153-163). Florham Park, NJ: Macmillan.
10. Fowler, J. S., Volkow, N. D., Wang, G. J., Pappas, N., Logan, J., MacGregor, R., Alexoff, D., Shea, C., Schlyer, D., Wolf, A. P., Warner, D., Zezulkova, I., & Cliento, R. (1996). Inhibition of monoamine oxidase B in the brains of smokers. Nature, 379, 733-736.
11. Haertzen, C. A., & Hickey, J. E. (1987). Addiction Research Center Inventory (ARCI): Measurement of euphoria and other drug effects. In M. A. Bozarth (Ed.), Methods of assessing the reinforcing properties of abused drugs. New York: Springer.
12. Koob, G. F., & Bloom, F. E. (1988). Cellular and molecular mechanisms of drug dependence. Science, 242, 715-723.
13. May, P. R. A., Lee, M. A., & Bacon, R. C. (1983). Quantitative assessment of neuroleptic-induced extrapyramidal symptoms: Clinical and nonclinical approaches. Clinical Neuropharmacology, 6(Suppl. 1), S35-S51.
14. McGehee, D. S., Heath, M. J. S., Gelber, S., Devay, P., & Role, L. W. (1995). Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science, 269, 1692-1696.
15. McNair, D. M., Lorr, M., & Droppelman, L. F. (1981). EITS manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service.
16. Nelson, M. V., Berchou, R. C., Kareti, D., & LeWitt, P. A. (1990). Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clinical Pharmacology and Therapeutics, 47, 694-697.
17. Pontieri, F. E., Tanda, G., Orzi, F., & Di Chiara, G. (1996). Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature, 382, 255-257.
18. Schuster, C. R., Lucchesi, B. R., & Emley, G. S. (1979). The effects of d-amphetamine meprobamate and lobeline on the cigarette smoking behavior of normal human subjects. In N. A. Krasnegor (Ed.), Cigarette smoking as a dependence process (National Institute on Drug Abuse Research Monograph No. 23, pp. 91-99). Washington, DC: U.S. Government Printing Office.
19. Seeman, P. (1990). Atypical neuroleptics: Role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiatrica Scandinavica. Supplementum, 358, 19-20.
20. Shiffman, S. M., & Jarvik, M. E. (1976). Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology, 50, 35-39.
21. Uematsu, T., Matsuno, H., Sato, H., Hirayama, H., Hasegawa, K., & Nakashima, M. (1992). Steady-state pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients: Analysis of factors determining their concentration in hair. Journal of Pharmaceutical Sciences, 81, 1008-1011.
22. Vance, M. L., Evans, W. S., & Thorner, M. O. (1984). Drugs five years later: Bromocriptine. Annals of Internal Medicine, 100, 78-91.
23. Wirshing, W. C., Cummings, J. L., Dencker, S. J., & May, P. R. A. (1991). Electromechanical characteristics of tardive dyskinesia. Journal of Neuropsychiatry and Clinical Neurosciences, 3, 10-17.
24. Wise, R. A., & Rompre, P. P. (1989). Brain dopamine reward. Annual Review of Psychology, 40, 191-225.